Novel Glycolysis-Related Gene Signature Developed in Renal Cell Carcinoma
Posted: Wednesday, January 6, 2021
Researchers in China have developed a novel glycolysis-related risk signature that appears to be associated with disease progression, prognosis, and immune microenvironment of renal cell carcinoma. Tie Chong, MD, of Xi’an Jiaotong University, Shaanxi, China, and colleagues also identified three core glycolytic risk genes—CD44, PLOD1, and PLOD2—that seem to be capable of promoting the proliferation and invasion of renal cancer cells. “Our findings can provide new inspirations for renal cell carcinoma prognostic analysis and treatment,” stated the authors. Their research was published in BMC Cancer.
The authors selected seven glycolysis-related gene sets from the Molecular Signatures Database (MSigDB) and utilized The Cancer Genome Atlas (TCGA) database to construct the glycolysis-related gene signature. In the 537 renal cell carcinoma samples from TCGA that were analyzed, 4 glycolysis-related gene sets were significantly enriched. A total of 261 glycolysis-related genes from the 4 enriched gene sets were selected for further analyses.
Ultimately, eight differentially expressed genes were included in the glycolytic risk signature—CD44, PLOD2, KIF20A, IDUA, PLOD1, HMMR, DEPDC1, and ANKZF1. These genes were significantly enriched in renal cell carcinoma samples and identified as an independent prognostic factor for renal cell carcinoma (hazard ratio = 1.204). Analyses revealed that silencing of CD44, PLOD1, and PLOD2 suppressed renal cancer cells' proliferation and invasion, indicating that they may serve as renal cell carcinoma oncogenes.
Based on this risk signature, renal cell carcinoma cases classified in the high-risk group were associated with a higher proportion of death events and undesirable clinicopathologic features. “These results indicate that the risk signature based on glycolytic genes not only affects renal cell carcinoma prognosis, but also is closely associated with renal cell carcinoma malignant progression.”
Disclosure: The study authors reported no conflicts of interest.